about
Transcriptome Analysis of Ullrich Congenital Muscular Dystrophy Fibroblasts Reveals a Disease Extracellular Matrix Signature and Key Molecular RegulatorsBone marrow transplantation in dysferlin-deficient mice results in a mild functional improvement.Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg.Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy.Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells.Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy.Analysis of serum miRNA profiles of myasthenia gravis patients.Alterations in cerebral white matter and neuropsychology in patients with cirrhosis and fallsThe TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations.Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function.1α,25(OH)(2)-Vitamin D3 increases dysferlin expression in vitro and in a human clinical trial.Prognostic value of X-chromosome inactivation in symptomatic female carriers of dystrophinopathyMuscle MRI in muscular dystrophiesThe Clinical Outcome Study for dysferlinopathy: An international multicenter study.Treatment strategies for myasthenia gravis.Treatment strategies for myasthenia gravis: an update.Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck.Globular adiponectin as a complete mesoangioblast regulator: role in proliferation, survival, motility, and skeletal muscle differentiation.Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis.Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies.Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.Favorable outcome of ischemic stroke in patients pretreated with statins.The increase of pericyte population in human neuromuscular disorders supports their role in muscle regeneration in vivo.Teaching Video NeuroImages: The Beevor sign in late-onset Pompe disease.Corpus callosum agenesis, myopathy and pinpoint pupils: consider Stormorken syndrome.Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy.Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.Muscle imaging in muscle dystrophies produced by mutations in the EMD and LMNA genes.Severe exacerbation of Andersen-Tawil syndrome secondary to thyrotoxicosis.Genetic and epigenetic determinants of low dysferlin expression in monocytes.Cranial, axial and proximal myopathy and hypertrophic cardiomyopathy caused by a mutation in the globular head region of the MYH7 gene.Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity.[Toxic demyelinating neuropathy and leukoencephalopathy in patients who take the slimming products Thermatrim ® and Pura Alegria ®].Blood pressure is not associated with haematoma enlargement in acute intracerebral haemorrhage.Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials.Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort.Cortactin autoantibodies in myasthenia gravis.Long-lasting treatment effect of rituximab in MuSK myasthenia.Antibodies against cell adhesion molecules and neural structures in paraneoplastic neuropathies.
P50
Q28271052-960EA1E2-0FB7-478E-9B02-843D83E8F385Q30552419-B7702623-0031-458A-9BC8-2583484B00CDQ30574385-FEFC142E-A4A7-4D0C-980A-AF0D86409E0CQ31043843-CBFC6B24-0C00-4CE5-A326-B0EF857492C3Q33559684-C3455124-3EF4-401F-B4F1-31467457E38BQ33833512-400D88F2-4D6E-417E-8F60-EF4C5C065838Q35122838-4E2E68D0-9FF9-4196-8090-E7193F0DE649Q35203206-E82770AE-F865-4ECE-A35C-8240E257BD65Q35508913-33B3DE2D-B430-4200-936C-224F82E7E864Q36154874-368C8605-980A-4286-A68D-A22FDF97201AQ36298643-F1522A62-99D0-4604-B977-0F55E49D352CQ36380483-3FC98732-0811-4E00-BAE2-EFBB6AAD7A8AQ36876584-334A441A-2D5E-4B1E-8BCD-6CF56C089CC4Q37197499-52BDFE8D-1018-4E81-9D56-A6C1EEEF92D0Q37483922-EF1F2C64-2406-4F49-8E02-071963CC6937Q38024858-CC2CAFA7-8126-40C2-AD02-C64B29BC7004Q39322545-F61D7F47-0B4D-41FE-ADB2-26F137847E2AQ39570584-ECBAC1E5-C827-4978-AFC8-762AEB6DAD03Q39630889-9B1586DA-891E-4BBB-8C69-42C2F53B38F7Q42233198-2697DA5E-5EB4-4050-89E8-2A9A73CE9469Q43007239-1EEFAAD9-0DC4-4665-8E8B-FA273FE18ADBQ43114504-CCA031EB-F036-42D3-8750-BED755D46C64Q44836885-4EE73CB0-D3F1-4F62-96E9-23C3539D96F4Q47322422-1F6B3878-FE54-4B86-8C9E-0A08C48C2479Q48002098-857F97CC-22AA-4EBA-B813-5A58831EAA75Q48196856-9DBF1496-3E65-4A1A-AAC7-4C6041106ACDQ48229967-353F319F-8D5E-451B-B0C9-A82DF7292221Q49023332-C78D4CEE-4431-4BC1-BC96-2763E7546D43Q50277807-75FDEFF0-3820-40DF-BA0E-6DFC74D59689Q50470772-E81E6E5D-7708-4982-AF15-8B2FEE7CD326Q50471072-EAA99884-56CB-48CE-B609-CC766198B07AQ50472029-2A96C9FA-9DC8-4F32-9FFE-52C4A96A3A35Q50717069-211574ED-D2A3-48BB-9E28-AFA5F5A362E1Q52839161-27E11F1D-FBC8-43A0-AED1-7A41BFA10D3FQ53397871-FE39960D-D68E-4738-9313-E4CF267BE025Q53511615-0426EE68-21C3-438B-BB17-3ED7B7A78AAAQ54270728-3A250EC0-1ABE-4B75-90EA-3E6D454765B2Q54324670-A3E808EC-4A72-4E05-9284-E0DF2EB947F4Q54538565-DA5DFCAF-A1A5-46F0-AE5F-D7869F336385Q55017224-0FFFBDA6-9F22-470E-BEF0-7471993F52AC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jordi Díaz-Manera
@ast
Jordi Díaz-Manera
@en
Jordi Díaz-Manera
@es
Jordi Díaz-Manera
@nl
Jordi Díaz-Manera
@sl
type
label
Jordi Díaz-Manera
@ast
Jordi Díaz-Manera
@en
Jordi Díaz-Manera
@es
Jordi Díaz-Manera
@nl
Jordi Díaz-Manera
@sl
prefLabel
Jordi Díaz-Manera
@ast
Jordi Díaz-Manera
@en
Jordi Díaz-Manera
@es
Jordi Díaz-Manera
@nl
Jordi Díaz-Manera
@sl
P106
P21
P31
P496
0000-0003-2941-7988